Gene Therapy Player UniQure To Lay Off 20% Of Workforce, Stop Parkinson's Study
Portfolio Pulse from Vandana Singh
UniQure N.V. (NASDAQ:QURE) plans to cut 20% of its workforce, or about 114 jobs, and discontinue more than half of its research and technology projects, including AMT-210 for Parkinson's disease. The restructuring is expected to generate savings of about $180 million over the next three years. The company will consolidate all manufacturing into its Lexington, MA facility and consolidate process and analytical development into its Amsterdam, Netherlands facility. Chief Scientific Officer Ricardo Dolmetsch will leave the company as part of the restructuring.
October 05, 2023 | 2:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UniQure's restructuring plan, including workforce reduction and discontinuation of several research projects, is expected to save the company $180 million over the next three years. This could potentially improve the company's financial health in the long term.
The restructuring plan, including job cuts and discontinuation of several research projects, is a cost-saving measure that could potentially improve the company's financial health in the long term. However, the discontinuation of research projects could impact the company's future product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100